Bioatla Inc
BCAB0.753USD
-0.039-4.89%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
44.29MMarket Cap
LossP/E TTM
More Details of Bioatla Inc Company
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), evalstotug (BA3071), and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugate that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Bioatla Inc Info
Ticker SymbolBCAB
Company nameBioatla Inc
IPO dateDec 16, 2020
CEOShort (Jay M)
Number of employees61
Security typeOrdinary Share
Fiscal year-endDec 16
Address11085 Torreyana Road
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92121
Phone18585580708
Websitehttps://www.bioatla.com/
Ticker SymbolBCAB
IPO dateDec 16, 2020
CEOShort (Jay M)
Company Executives of Bioatla Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jay M. Short, Ph.D.
Dr. Jay M. Short, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.27M
+29.74%
Dr. Eric L. Sievers, M.D.
Dr. Eric L. Sievers, M.D.
Chief Medical Officer
Chief Medical Officer
459.98K
+12.99%
Mr. Richard A. Waldron
Mr. Richard A. Waldron
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
446.16K
+14.72%
Dr. Lawrence Steinman, M.D.
Dr. Lawrence Steinman, M.D.
Lead Independent Director
Lead Independent Director
137.27K
-4.85%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
136.20K
-4.89%
Dr. Susan Moran, M.D.
Dr. Susan Moran, M.D.
Independent Director
Independent Director
111.11K
-5.93%
Mr. Edward L. (Eddie) Williams
Mr. Edward L. (Eddie) Williams
Independent Director
Independent Director
--
--
Mr. Scott A. Smith
Mr. Scott A. Smith
Director
Director
--
--
Ms. Sylvia Mcbrinn
Ms. Sylvia Mcbrinn
Independent Director
Independent Director
--
--
Mr. Christian Vasquez, CPA
Mr. Christian Vasquez, CPA
Chief Accounting Officer, Controller, Corporate Secretary
Chief Accounting Officer, Controller, Corporate Secretary
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jay M. Short, Ph.D.
Dr. Jay M. Short, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
3.27M
+29.74%
Dr. Eric L. Sievers, M.D.
Dr. Eric L. Sievers, M.D.
Chief Medical Officer
Chief Medical Officer
459.98K
+12.99%
Mr. Richard A. Waldron
Mr. Richard A. Waldron
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
446.16K
+14.72%
Dr. Lawrence Steinman, M.D.
Dr. Lawrence Steinman, M.D.
Lead Independent Director
Lead Independent Director
137.27K
-4.85%
Dr. Mary Ann Gray, Ph.D.
Dr. Mary Ann Gray, Ph.D.
Independent Director
Independent Director
136.20K
-4.89%
Dr. Susan Moran, M.D.
Dr. Susan Moran, M.D.
Independent Director
Independent Director
111.11K
-5.93%
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Acorn Capital Advisors, LLC
8.19%
Short (Jay M)
5.54%
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
4.76%
The Vanguard Group, Inc.
3.30%
Tang Capital Management, LLC
2.33%
Other
75.88%
Shareholders
Shareholders
Proportion
Acorn Capital Advisors, LLC
8.19%
Short (Jay M)
5.54%
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
4.76%
The Vanguard Group, Inc.
3.30%
Tang Capital Management, LLC
2.33%
Other
75.88%
Shareholder Types
Shareholders
Proportion
Investment Advisor
20.34%
Individual Investor
11.53%
Hedge Fund
4.82%
Investment Advisor/Hedge Fund
2.89%
Research Firm
0.47%
Bank and Trust
0.08%
Venture Capital
0.03%
Private Equity
0.02%
Other
59.82%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
192
16.91M
63.24%
--
2025Q3
207
16.91M
67.36%
-559.35K
2025Q2
211
17.47M
64.32%
-1.73M
2025Q1
221
18.40M
68.72%
-21.73M
2024Q4
247
24.83M
70.63%
+3.61M
2024Q3
244
21.78M
92.51%
-5.23M
2024Q2
251
26.26M
99.14%
-3.16M
2024Q1
260
29.54M
100.29%
-18.70M
2023Q4
268
31.14M
105.10%
-1.86M
2023Q3
274
32.99M
106.52%
-1.91M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Acorn Capital Advisors, LLC
4.84M
8.23%
--
--
Jun 30, 2025
Short (Jay M)
2.52M
4.3%
-6.35K
-0.25%
Aug 31, 2025
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
3.55M
6.04%
+3.55M
--
Mar 06, 2025
The Vanguard Group, Inc.
1.78M
3.04%
-34.85K
-1.92%
Jun 30, 2025
Tang Capital Management, LLC
1.37M
2.34%
--
--
Jun 30, 2025
Acadian Asset Management LLC
1.49M
2.54%
-197.56K
-11.69%
Jun 30, 2025
Smith Scott Andrew
852.35K
1.45%
+23.50K
+2.84%
Jun 18, 2025
Renaissance Technologies LLC
754.24K
1.28%
+9.41K
+1.26%
Jun 30, 2025
Short (Carolyn Anderson)
1.35M
2.31%
--
--
Apr 21, 2025
Aguja Capital GmbH
750.00K
1.28%
--
--
Apr 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 ETF
0%
Formidable ETF
0%
Global X Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
View more
Avantis US Small Cap Equity ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Formidable ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
DFA Dimensional US Sustainability Core 1 ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Bioatla Inc?
The top five shareholders of Bioatla Inc are:
Acorn Capital Advisors, LLC holds 4.84M shares, accounting for 8.23% of the total shares.
Short (Jay M) holds 2.52M shares, accounting for 4.30% of the total shares.
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A. holds 3.55M shares, accounting for 6.04% of the total shares.
The Vanguard Group, Inc. holds 1.78M shares, accounting for 3.04% of the total shares.
Tang Capital Management, LLC holds 1.37M shares, accounting for 2.34% of the total shares.
Acorn Capital Advisors, LLC holds 4.84M shares, accounting for 8.23% of the total shares.
Short (Jay M) holds 2.52M shares, accounting for 4.30% of the total shares.
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A. holds 3.55M shares, accounting for 6.04% of the total shares.
The Vanguard Group, Inc. holds 1.78M shares, accounting for 3.04% of the total shares.
Tang Capital Management, LLC holds 1.37M shares, accounting for 2.34% of the total shares.
What are the top three shareholder types of Bioatla Inc?
The top three shareholder types of Bioatla Inc are:
Acorn Capital Advisors, LLC
Short (Jay M)
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
Acorn Capital Advisors, LLC
Short (Jay M)
OPOKA Towarzystwo Funduszy Inwestycyjnych S.A.
How many institutions hold shares of Bioatla Inc (BCAB)?
As of 2025Q4, 192 institutions hold shares of Bioatla Inc, with a combined market value of approximately 16.91M, accounting for 63.24% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.12%.
What is the biggest source of revenue for Bioatla Inc?
In --, the -- business generated the highest revenue for Bioatla Inc, amounting to -- and accounting for --% of total revenue.
